JPH0154327B2 - - Google Patents
Info
- Publication number
- JPH0154327B2 JPH0154327B2 JP6254779A JP6254779A JPH0154327B2 JP H0154327 B2 JPH0154327 B2 JP H0154327B2 JP 6254779 A JP6254779 A JP 6254779A JP 6254779 A JP6254779 A JP 6254779A JP H0154327 B2 JPH0154327 B2 JP H0154327B2
- Authority
- JP
- Japan
- Prior art keywords
- methanesulfonate
- betahistine
- spherules
- active ingredient
- spraying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960004536 betahistine Drugs 0.000 claims description 22
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 21
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 230000006872 improvement Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000027530 Meniere disease Diseases 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 208000009205 Tinnitus Diseases 0.000 description 5
- 208000012886 Vertigo Diseases 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 231100000886 tinnitus Toxicity 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 231100000889 vertigo Toxicity 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000012826 adjustment disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- PIIWYFURBFSHKM-UHFFFAOYSA-N n-methyl-2-pyridin-2-ylethanamine;hydrochloride Chemical group Cl.CNCCC1=CC=CC=N1 PIIWYFURBFSHKM-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010008097 Cerebral circulatory failure Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001392 betahistine hydrochloride Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6254779A JPS55154915A (en) | 1979-05-21 | 1979-05-21 | Medicine mold |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6254779A JPS55154915A (en) | 1979-05-21 | 1979-05-21 | Medicine mold |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55154915A JPS55154915A (en) | 1980-12-02 |
| JPH0154327B2 true JPH0154327B2 (enrdf_load_stackoverflow) | 1989-11-17 |
Family
ID=13203364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6254779A Granted JPS55154915A (en) | 1979-05-21 | 1979-05-21 | Medicine mold |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS55154915A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011520992A (ja) * | 2008-05-27 | 2011-07-21 | ザ ユニバーシティー オブ メルボルン | エウスタキオ管機能障害を有する哺乳動物の治療方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4914084A (en) * | 1984-05-09 | 1990-04-03 | Synthetic Blood Corporation | Composition and method for introducing heme, hemoproteins, and/or heme-hemoprotein complexes into the body |
| WO2005101979A2 (en) * | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
-
1979
- 1979-05-21 JP JP6254779A patent/JPS55154915A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011520992A (ja) * | 2008-05-27 | 2011-07-21 | ザ ユニバーシティー オブ メルボルン | エウスタキオ管機能障害を有する哺乳動物の治療方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55154915A (en) | 1980-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4587118A (en) | Dry sustained release theophylline oral formulation | |
| JP4573397B2 (ja) | 速崩壊性固形製剤 | |
| CN101987081B (zh) | 一种控释制剂 | |
| JPH10510559A (ja) | シサプリドの即時放出性ｐＨ非依存性固形製剤 | |
| FR2523845A1 (fr) | Preparations therapeutiques a liberation prolongee a base d'hydroxypropylmethylcellulose de poids moleculaire eleve | |
| US4155993A (en) | Prolonged-release pharmaceutical compositions for oral administration, their methods of making and use | |
| US10335443B2 (en) | Orodispersible film | |
| US5310560A (en) | Medicine for the treatment of illnesses of the respiratory organs | |
| JPS62501845A (ja) | 制御放出塩化カリウム | |
| US4229428A (en) | Galenical form of administration of betahistine and its derivatives | |
| JPWO2013115171A1 (ja) | 苦味マスク顆粒含有口腔内崩壊錠 | |
| JP2008536922A (ja) | オランザピンの医薬用経口崩壊錠 | |
| JPH0729916B2 (ja) | 鎮痛性を有する医薬組成物 | |
| US10864165B2 (en) | Super-rapid disintegrating tablet, and method for producing same | |
| RU2563190C2 (ru) | Лекарственное средство на основе сухих экстрактов лекарственных растений и способ его получения (варианты) | |
| US10426732B2 (en) | Rapidly disintegrating tablet, and method for producing same | |
| JPH0154327B2 (enrdf_load_stackoverflow) | ||
| CN115089618B (zh) | 一种用于防治骨质疏松的药物组合物及其制备方法 | |
| US5077294A (en) | Products containing verapamil or gallopamil and prazosin | |
| GB2130087A (en) | Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions | |
| RU2801279C1 (ru) | Фармацевтическая композиция противодиабетического действия в твердой лекарственной форме в виде таблеток | |
| US20180318228A1 (en) | Method for a slow release of drugs from orally dissolving capsules | |
| CN108379237A (zh) | 一种治疗泌尿道感染的药物微囊制剂及其制备方法 | |
| US2598530A (en) | Enteric coated pyranisamine | |
| Bhesaniya et al. | ORODISPERSIBLE MINI-TABLETS: A REVIEW. |